Montelucaste Generis (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related mediators from binding. This inhibition reduces bronchoconstriction, airway edema, and inflammatory cell recruitment, leading to improved airflow and decreased allergic inflammation.

The specific dose is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Healthcare professionals follow approved dosing guidelines, and patients should follow the prescriber’s instructions without altering the regimen.

Pregnancy category for montelukast is not definitively established. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; the decision should be made by a healthcare provider after weighing benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a tablet formulation, but it may be less potent than inhaled steroids for severe disease and is often used as add‑on therapy.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged or the product appears discoloured.

Montelucaste Generis is taken orally as a tablet, swallowed whole with water. It can be taken with or without food, once daily, at the same time each day to maintain consistent blood levels.

Serious adverse events include neuropsychiatric reactions such as depression, anxiety, suicidal thoughts, and rare allergic responses like angioedema or anaphylaxis. Clinicians should monitor patients for mood changes and any signs of severe hypersensitivity, and advise immediate medical attention if such symptoms occur.

Montelucaste Generis should be avoided in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, and it is not recommended for use in children under the approved age for the specific indication.